๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Locally Advanced Nasopharyngeal Carcinoma

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. NCT06059261Phase 21 site๐Ÿ“ Chongqing Chongqing University Cancer Hospital ยท Tests: Envafolimab and recombinant human endostatin combined with chemoradiotherapy Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy NCT05892354NA20 sites๐Ÿ“ Fuzhou๐Ÿ“ Fuzhou๐Ÿ“ Guangzhou First Affiliated Hospital of Guangxi Medical University ยท Tests: Enteral immunonutrition, Standard enteral nutrition Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy NCT05674305Phase 31 site๐Ÿ“ Shanghai Fudan University ยท Tests: Radiotherapy, Cisplatin GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Toripalimab, Anlotinib, Gemcitabine, Cisplatin, radiation Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. NCT07781358Phase 21 site๐Ÿ“ Shanghai Hongmeng Yu ยท Tests: Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC NCT06182657n/a1 site๐Ÿ“ Nanchang Jiangxi Provincial Cancer Hospital Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy NCT07496190Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug vedotin, Becotatug vedotin Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma NCT05860868Phase 31 site๐Ÿ“ Guangzhou First Affiliated Hospital, Sun Yat-Sen University ยท Tests: 2 cycles induction chemotherapy, 3 cycles induction chemotherapy A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors NCT06475300Phase 21 site๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma NCT05062005Phase 31 site๐Ÿ“ Guangzhou First Affiliated Hospital, Sun Yat-Sen University ยท Tests: Induction Chemotherapy, Concurrent Chemotherapy, Definitive Radiotherapy Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC NCT06235203Phase 37 sites๐Ÿ“ Shanghai๐Ÿ“ Fuzhou๐Ÿ“ Nanning Eye & ENT Hospital of Fudan University ยท Tests: endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experiโ€ฆ PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC NCT07332247Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Selective re-irradiation, Immediate re-irradiation A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites๐Ÿ“ Sacramento๐Ÿ“ Celebration๐Ÿ“ Miami Marengo Therapeutics, Inc. ยท Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Nituzumab (Taixinsheng ยฎ๏ผ‰ A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma NCT05508347Phase 21 site๐Ÿ“ Chengdu Sichuan Cancer Hospital and Research Institute ยท Tests: Nituzumab/placebo Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma NCT04437329Phase 31 site๐Ÿ“ Guangzhou Affiliated Cancer Hospital & Institute of Guangzhou Medicalโ€ฆ ยท Tests: Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin, Cisplatin, Intensity modulated-radโ€ฆ Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study NCT05946577n/a1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT NCT05628922Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Toripalimab, Induction chemotherapy and concurrent chemoradiation Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. NCT05397769Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Envafolimab Plus Chemoradiotherapy Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy NCT05772208Phase 31 site๐Ÿ“ Shanghai Fudan University ยท Tests: Camrelizumab, Nimotuzumab, neoadjuvant chemotherapy and CCRT Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma NCT04136886Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Cisplatin, IMRT Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma NCT07177443Phase 31 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: Radiotherapy, Serplulimab, Cisplatin Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma NCT07362979Phase 24 sites๐Ÿ“ Dongguan๐Ÿ“ Guangzhou๐Ÿ“ Shenzhen Sun Yat-sen University ยท Tests: GP plus Toripalimab Induction chemotherapy+CCRT, TP plus Toripalimab Induction chemotherapy+CCRT, TPC plus Toripalimab โ€ฆ Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC NCT07085234Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor NCT05194982Phase 18 sites๐Ÿ“ Chongqing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1 A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma NCT07392320Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: TP+PD1+CCRT, PD-1 Monoclonal Antibody, Capecitabine Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC NCT06811844Phase 23 sites๐Ÿ“ Xiamen๐Ÿ“ Zhangzhou๐Ÿ“ Haikou The First Affiliated Hospital of Xiamen University ยท Tests: Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy NCT07328841Phase 312 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ming-Yuan Chen ยท Tests: Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy, Reduced-dose radiotheโ€ฆ Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma NCT07706985Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Toripalimab combined with Nimotuzumab, Nimotuzumab AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) NCT07038343Phase 1, Phase 227 sites๐Ÿ“ Gilbert๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Avenzo Therapeutics, Inc. ยท Tests: AVZO-1418, Combination Agent 1, Combination Agent 2 VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites๐Ÿ“ Santa Rosa๐Ÿ“ Hartford๐Ÿ“ Washington D.C. VM Oncology, LLC ยท Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy